A Pinter, L J Green, J Selmer, M Praestegaard, L S Gold, M Augustin, trial investigator group
Issues - Febbraio 2022
A Pinter, L J Green, J Selmer, M Praestegaard, L S Gold, M Augustin, trial investigator group
K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, M C Fargnoli, M Esposito, P Amerio, G Gualdi, L Bianchi, L Stingeni
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):e111-e113Deepak M W Balak, Stefano Piaserico, Ismail Kasujee
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Psoriasis (Auckl). 2021 Dec 7;11:151-168A Al-Janabi, Z Z N Yiu
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Psoriasis (Auckl). 2022 Jan 6;12:1-14D Thaçi, K Eyerich, A Pinter, M Sebastian, K Unnebrink, S Rubant, D A Williams, P Weisenseel
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial
Br J Dermatol. 2022 Jan;186(1):30-39Mark Lebwohl, Richard G Langley, Carle Paul, Lluis Puíg, Kristian Reich, Peter van de Kerkhof, Hsiuan-Lin Wu, Sven Richter, Shauna Jardon, Paolo Gisondi
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
Dermatol Ther (Heidelb). 2022 Jan;12(1):61-78Shinichi Imafuku, Yayoi Tada, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy
Dermatol Ther (Heidelb). 2022 Jan;12(1):121-135Y Lytvyn, J R Georgakopoulos, A Mufti, A R Devani, M J Gooderham, V Jain, P Lansang, R Vender, V H Prajapati, J Yeung